광범위큰B세포림프종에 대한 키메릭항원수용체T세포 (Chimeric Antigen Receptor T-cells) 치료
Chimeric Antigen Receptor T-Cell Therapy for Diffuse Large B-Cell Lymphoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
Abstract
CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a genetically engineered cell therapy, showed unprecedented efficacy in the treatment of relapsed or refractory diffuse large B-cell lymphoma. Two agents, axicabtagene ciloleucel and tisagenlecleucel, were approved by the Food and Drug Administration in 2017. However, CAR-T therapy is a treatment with complex logistics and high costs, as well as inherent adverse events, including cytokine-release syndrome and neurotoxicity. In addition, predictive biomarkers for efficacy and toxicity are lacking. Industry-academy cooperation is urgently required to develop CAR-T therapy that is effective, safe, and affordable for patients in Korea.
참고문헌 (26)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2018", Cancer Research and Treatment, 50(2), pp.317~323 (2018), 대한암학회
- 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study", Journal of Pathology and Translational Medicine, 45(3), pp.254~260 (2011), 대한병리학회
- Sehn LH, "Diffuse large B-cell lymphoma : optimizing outcome in the context of clinical and biologic heterogeneity", Blood, 125, pp.22~32 (2015)
- Gisselbrecht C, "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era", J Clin Oncol, 28, pp.4184~4190 (2010)
- Crump M, "Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study", Blood, 130, pp.1800~1808 (2017)
- Gross G, "Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity", Proc Natl Acad Sci U S A, 86, pp.10024~10028 (1989)
- Eshhar Z, "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors", Proc Natl Acad Sci U S A, 90, pp.720~724 (1993)
- Finney HM, "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product", J Immunol, 161, pp.2791~2797 (1998)
- Brentjens RJ, "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15", Nat Med, 9, pp.279~286 (2003)
- Maher J, "Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta", CD28 receptor, 2002, pp.20, 70~75
- Eshhar Z, "The emergence of T-bodies", CAR T cells, 2014, pp.20, 123~126
- Kochenderfer JN, "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19", Blood, 116, pp.4099~4102 (2010)
- Porter DL, "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia", N Engl J Med, 365, pp.725~733 (2011)
- Davila ML, "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia", Sci Transl Med, 6, pp.224ra225~ (2014)
- Turtle CJ, "CD19 CAR-T cells of defined CD4+ : CD8+ composition in adult B cell ALL patients", J Clin Invest, 126, pp.2123~2138 (2016)
- Turtle CJ, "Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells", Sci Transl Med, 8, pp.355ra116~ (2016)
- Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
- Locke FL, "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1) : a single-arm, multicentre, phase 1-2 trial", Lancet Oncol, 20, pp.31~42 (2019)
- Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma", N Engl J Med, 380, pp.45~56 (2019)
- Schuster SJ, "Chimeric antigen receptor T cells in refractory B-cell lymphomas", N Engl J Med, 377, pp.2545~2554 (2017)
- Abramson JS, "Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel(JCAR017)in R", R aggressive NHL, 2018, pp.36, 7505~
- Nastoupil LJ, "Axicabtagene ciloleucel(Axi-cel)CD19 chimeric antigen receptor(CAR)T-cell therapy for relapsed", refractory large B-cell lymphoma : real world experience, 2018, pp.132, 91~
- Jacobson CA, "Axicabtagene ciloleucel in the real world : outcomes and predictors of response, resistance and toxicity", Blood, 132, pp.92~ (2018)
- Yoon DH, "Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells(CAR-Ts) : combination or built-in CAR-T", Int J Mol Sci, 19, pp.E340~ (2018)
- Fry TJ, "CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy", Nat Med, 24, pp.20~28 (2018)
- Chu F, "Targeting CAR T resistance due to CD19 loss with CD79b-specific CAR T cells in B-cell malignancies", Blood, 132, pp.1662~ (2018)